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BACKGROUND: This phase Ib trial assessed safety, tolerability, and maximum tolerated dose (MTD) of figitumumab (CP-751,871), a fully
human monoclonal antibody targeting the insulin-like growth factor type 1 receptor (IGF-IR), in combination with docetaxel.
METHODS: Patients with advanced solid tumours were treated with escalating dose levels of figitumumab plus 75mgm
–2 docetaxel
every 21 days. Safety, efficacy, pharmacokinetics (PKs), and biomarker responses were evaluated.
RESULTS: In 46 patients, no dose-limiting toxicities were attributable to the treatment combination. Grade 3 and 4 toxicities included
neutropaenia (n¼28), febrile neutropaenia (n¼11), fatigue (n¼10), leukopaenia (n¼7), diarrhoea (n¼5), hyperglycaemia,
lymphopaenia, cellulitis, DVT, and pain (all n¼1). The MTD was not reached. Four partial responses were observed; 12 patients had
disease stabilisation of X6 months. Pharmacokinetic and biomarker analyses showed a dose-dependent increase in plasma exposure,
and complete sIGF-IR downregulation at doses of X3mgkg
–1. Pharmacokinetics of docetaxel in combination was similar to when
given alone. Out of 18 castration-resistant prostate cancer patients, 10 (56%) had X5 circulating tumour cells (CTCs) per 7.5ml of
blood at baseline: 6 out of 10 (60%) had a decline from X5t oo5 CTCs and 9 out of 10 (90%) had a X30% decline in CTCs after
therapy.
CONCLUSIONS: Figitumumab and docetaxel in combination are well tolerated. Further evaluation is warranted.
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Alterations in the expression of components of the insulin-like
growth factor (IGF) signalling pathway have been shown to have a
critical role in the development of a variety of human malig-
nancies, including lung, breast, prostate, thyroid, colorectal
cancers, and sarcomas (Hankinson et al, 1998; Chang et al, 2002;
Cardillo et al, 2003; Durai et al, 2005; Pollak, 2008). The IGF type 1
receptor (IGF-IR) pathway, initiated by the ligands IGF-1 and
IGF-2, is associated with cellular mitogenesis, angiogenesis,
tumour cell survival, and tumourigenesis in various tumour cell
lines (Kalli et al, 2002; Kurmasheva and Houghton, 2006; Samani
et al, 2007). Inhibition of IGF-IR in a range of tumour types has
antiproliferative effects and synergises with other anticancer
therapies, including cytotoxic chemotherapies (Benini et al, 2001;
Cohen et al, 2005; Yin et al, 2005; Abe et al, 2006). Preclinical
models have shown evidence of chemosensitisation of androgen-
independent human prostate cancer cells when IGF-IR blockade
was combined with either cisplatin, mitoxantrone, or paclitaxel
(Hellawell et al, 2003). Inhibition of IGF-IR also enhanced
docetaxel antitumour activity in animal models of castration-
resistant prostate cancer (CRPC) (Cardillo et al, 2003), and
synergised with trastuzumab in HER2
þ breast cancer cells
(Esparı ´s-Ogando et al, 2008).
Figitumumab (CP-751,871) is a fully human IgG2 monoclonal
antibody (mAb) highly specific for IGF-IR. Figitumumab blocks
the binding of IGF-1 to IGF-IR, inhibits the downstream signalling
activated by both IGF-1 and IGF-2, and induces prolonged
receptor internalisation and degradation (Cohen et al, 2005). It
inhibits the growth of tumour xenografts derived from colon
(Colo-205), breast (MCF7), and lung (H460) cancer cell lines
(Cohen et al, 2005). Additive tumour growth inhibition was
observed when figitumumab was combined with adriamycin,
5-fluorouracil, or tamoxifen (Cohen et al, 2005), when compared
with either of these cytotoxic therapies alone.
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with solid tumours (Haluska et al, 2007) and myeloma (Lacy et al,
2008). The majority of adverse events were of grade 1 and 2, and
included elevated transaminases, hyperglycaemia, anorexia and
fatigue. Grade 3 hyperglycaemia was observed in one patient in the
study of Lacy et al (2008), alongside grade 3 elevated aspartate
aminotransferase (AST), whereas there was one episode each of
grade 3 elevated g-glutamyl transferase (GGT), arthralgia and
fatigue in the study of Haluska et al (2007). No dose-limiting
toxicities (DLTs) were observed in these phase I studies, in which
the maximum tolerated dose (MTD) was not reached, and the
maximal feasible dose and recommended phase II dose (RP2D)
was 20mgkg
–1every 3 or 4 weeks (Haluska et al, 2007; Lacy et al,
2008). On the basis of its ability to block IGF-IR and modulate
chemosensitivity, the addition of figitumumab to docetaxel may
improve the antitumour activity of single-agent docetaxel. This
phase I dose-escalation trial was designed to determine the safety,
tolerability, pharmacokinetic (PK), and pharmacodynamic (PD)
effects of figitumumab given in combination with docetaxel in
subjects with advanced solid tumours.
MATERIALS AND METHODS
Eligibility
Patients with histologic or cytologic confirmation of advanced
solid tumours refractory to standard therapy were eligible. Other
inclusion criteria included: age X18 years; Eastern Cooperative
Oncology Group performance status of 0 or 1; adequate bone
marrow, renal, and hepatic function (absolute neutrophil
count X1500ml
–1, haemoglobin X10g per 100ml, platelets
4100000ml
–1, creatinine clearance X30mlmin
–1, and total
bilirubin equal to or less than the institution upper limit of
normal (ULN), AST, and alanine aminotransferase (ALT)
p1.5 ULN); and use of adequate contraception in patients with
reproductive potential. Exclusion criteria included: anticancer
therapy or surgery within 4 weeks, excluding luteinising hormone-
releasing hormone (LHRH) analogues in prostate cancer patients;
severe hypersensitivity reaction to docetaxel or drugs formulated
in polysorbate 80; neuropathy of grade X1; symptomatic or
untreated brain metastases; pregnancy or lactation; significant
active cardiac disease; concomitant high-dose corticosteroids
(X100mg prednisone per day or equivalent); serious active
infection; and other uncontrolled significant medical illness.
The study protocol was approved by the ethics committee of the
Royal Marsden Hospital and all patients gave written informed
consent before any study procedures were performed. The study
was conducted to Good Clinical Practice (GCP) specifications in
accordance with the Declaration of Helsinki and its amendments.
Study design and objectives
This was an open-label, phase Ib trial performed at a single centre.
The primary objective was to define the RP2D of figitumumab
when given in combination with docetaxel. Secondary objectives
were to characterise the PK of figitumumab when given in
combination with docetaxel, to evaluate the effect of figitumumab
on the number of circulating tumour cells (CTCs) and their
expression of IGF-IR (Allard et al, 2004; de Bono et al, 2007), to
test for the occurrence of any antidrug antibody (ADA) response to
figitumumab, to monitor the efficacy of figitumumab when given
in combination with docetaxel, and to characterise the effect of
figitumumab on docetaxel PK.
Treatment
Figitumumab was administered intravenously (IV) after docetaxel
(75mgm
–2) on day 1 every 21 days at doses of 0.1–20mgkg
–1in
dose-doubling cohorts of three to six patients. Dose reduction of
docetaxel to 60mgm
–2 was permitted. In an expansion cohort to
evaluate PK drug–drug interaction (DDI), in cycle 1 docetaxel was
administered on day 1 followed by figitumumab on day 2; for
subsequent cycles, both agents were administered on day 1.
Patients were pre-medicated with oral dexamethasone 8mg twice
daily for 3 days starting at day –1. Patients continued treatment
with the combination or single-agent figitumumab if docetaxel was
discontinued, until disease progression or unacceptable toxicity
was observed.
Safety evaluation
Clinical and laboratory assessments for safety (physical examina-
tion, blood chemistry and haematology, urinalysis, adverse event,
and concomitant medication queries) were performed before
enrolment, before the next cycle, and at the end of treatment.
Doppler echocardiograms were performed at baseline, end of
cycles 1 and 6, end of study, and at follow-up (see below). Serum
samples for monitoring ADA were collected from all patients at
30min before dose in each cycle, at the end of study, and during
follow-up visits. When figitumumab plasma concentrations were
below the lower limit of quantification (LLOQ) of 120ngml
–1, the
ADA samples were analysed using a validated semiquantitative
enzyme-linked immunosorbent assay (ELISA). In brief, the ADA
samples were first incubated with figitumumab immobilised on a
microtitre plate. After removal of unbound material by washing,
anti-figitumumab antibodies were detected using biotinylated
figitumumab, followed by addition of streptavidin-horseradish
peroxidase conjugate and visualisation with 3,30,5,50-tetramethyl-
benzidine (TMB). The relative sensitivity of the assay was
approximately 1ngml
–1.
Toxicities were characterised according to the National Cancer
Institute Common Terminology Criteria for Adverse Events (NCI-
CTCAE), version 3.0. Radiologic (using Response Evaluation
Criteria in Solid Tumours-1 (RECIST) guidelines) and biochemical
evaluation of disease response was conducted every 6 weeks.
A DLT was defined as any one of the following adverse events
occurring during cycle 1 if considered related to study treatment:
(1) grade X3 gastrointestinal toxicity despite the use of adequate
medical intervention and/or prophylaxis; (2) any other grade X3
toxicity not classified under CTCAE blood/bone marrow (except
for grade 3 alopaecia and grade 3 g-glutamyl transpeptidase);
(3) grade 4 g-glutamyl transpeptidase; (4) grade 4 neutropaenia
(absolute neutrophil count o500cellsmm
–3) persisting for X7
consecutive days or complicated by fever (body temperature
438.01C or 1001F) and requiring hospitalisation; (5) asympto-
matic mitral thickening (45mm) with mitral regurgitation greater
than mild or valve gradient 45mmHg on echocardiogram, as
minor granulocytic and lymphocytic infiltration, oedema, and
deposition of myxomatous material was observed in the mitral
valve and subvalvular endocardium in preclinical testing; and (6)
grade 4 thrombocytopaenia (platelets o25000cellsmm
–3). The
use of colony-stimulating factors (G-CSF and GM-CSF) was
permitted for the management of recurrent febrile neutropaenia.
Evaluation of figitumumab and docetaxel PKs
For patients in the dose-escalation and expansion cohorts, blood
samples for the evaluation of figitumumab PKs were collected
before dose, and 1h and 1, 3, and 7 days after figitumumab dose in
cycles 1 and 4; predose in cycles 2, 3, 5, and beyond; and at the end
of the study. For patients enroled into the PK DDI cohort, blood
samples for evaluation of docetaxel PKs were collected in cycles
1 and 4 at pre-dose, 30, and 50min after the start of, and 30min
and 1, 3, 8, and 24h after the end of, docetaxel infusion. In addition,
blood samples for determination of figitumumab concentrations
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dose in cycles 1–6 and 1h after dose in cycle 4.
Plasma concentrations of figitumumab were analysed by a
validated ELISA as previously described (Haluska et al, 2007).
In brief, an IGF-1 soluble receptor extracellular domain was used
in this assay to capture figitumumab. Figitumumab bound to
the capturing receptor was then detected using horseradish
peroxidase-conjugated mouse anti-human IgG2. The LLOQ for
the assay was determined to be 120ngml
–1. Plasma concentrations
of docetaxel were determined using a validated high-performance
liquid chromatography method coupled with tandem mass
spectrometry (HPLC-MS/MS). The LLOQ of the HPLC-MS/MS
assay was 10ngml
–1.
Figitumumab and docetaxel plasma concentration–time data
were analysed by noncompartmental methods (Gibaldi and
Perrier, 1982) using WinNonlin version 3.2 (Pharsight, Mountain
View, CA, USA). For treatment cycles with sufficient figitumumab
PK data, area under the plasma concentration–time curve (AUC)
from time 0 to the last sampling time point with quantifiable
concentration within a cycle (AUClast) and from time 0 to the last
day of a cycle (AUC0–day22) were determined using the linear/log
trapezoidal approximation. The accumulation ratio of figitumu-
mab was calculated as the ratio of cycle 4 AUC0–day22 to cycle 1
AUC0–day22. For docetaxel PK, the peak plasma concentration
(Cmax) was determined by inspection of individual patient plasma
concentration–time data. AUClast values were determined using
the linear/log trapezoidal approximation. For comparison of
exposures of cycles 1 and 4, the Cmax and AUClast values were
normalised to dose level.
PD studies
Blood samples for the measurement of soluble (s)IGF-IR levels
and the enumeration of CTCs, including IGF-IR-expressing CTCs,
were collected from all patients on days 1 (before dosing of
figitumumab) and 8 of each treatment cycle, and at the end
of treatment. Total and IGF-IR-positive CTCs were isolated and
enumerated using the CellTracks system (Immunicon, Huntingdon
Valley, PA, USA) as previously described (de Bono et al, 2007).
The sIGF-IR levels were determined using an enzyme immunoas-
say that detects the extracellular domain of the IGF-IR (Pollak
et al, 2007; Pollak, 2008). The IGF-1R assay was validated
and performed in the laboratory of the co-author Dr Laurence
Demers. IGF-1R was determined in serum with a microtitre
plate ELISA method (reagents obtained from R&D Systems,
Minneapolis, MN, USA). The assay uses recombinant human
IGF-1R for the standard, a mouse anti-human IGF-1R capture
antibody, and a biotinylated detection antibody raised in goats.
The mouse anti-human IGF-1R capture antibody showed o1%
crossreactivity with IGF-1, IGF-II, and IGFBP 1-6. Assay sensitivity
was 0.1pgml
–1 and within-run imprecision was 5.3 and 7.1% at
IGF-1R concentrations of 8.4 and 0.52pgml
–1.
RESULTS
Patient characteristics
A total of 46 patients with a median age of 59.4 years (range
25–79) were enroled (Table 1). The most common tumour
types treated were CRPC (n¼22, 47.8%) and oesophageal cancer
(n¼9, 19.6%). Of the 28 patients who had received previous
chemotherapy, 3 had received at least one taxane-based
regimen. Patients received a median of 4.5 courses of figitumumab
(range 1–21) and a median of four courses of docetaxel (range
1–13). In all, 12 patients received X10 cycles of figitumumab
alone or with docetaxel. A dosing summary is provided in
Table 2.
Safety
Dose escalation of figitumumab proceeded safely from 0.1 to
20mgkg
–1 with no reported DLTs. One episode of grade 4
hyperglycaemia was observed during cycle 1 in a patient with
metastatic oesophageal cancer and a history of type II diabetes
mellitus treated with figitumumab at 20mgkg
–1. Another episode
of grade 2 hyperglycaemia was reported. Other figitumumab-
related toxicities are reported in Table 3 and include elevated ALT
(n¼5) and g-glutamyl transferase (n¼3), fatigue (n¼3), nausea
(n¼3), and muscle spasms (n¼3). Grade 3 and 4 toxicities related
to docetaxel (Table 3) reflected the expected toxicity profile for this
Table 1 Baseline characteristics
Characteristic N¼46
Age, years
Median 59.4
Range 25–79
Sex, n (%)
Male 40 (87)
Female 6 (13)
ECOG PS, n (%)
0 9 (19.6)
1 37 (80.4)
Tumour type, n (%)
CRPC 22 (47.8)
Oesophageal 9 (19.6)
GOJ 3 (6.5)
Sarcoma
a 3 (6.5)
Gastric 2 (4.3)
Cervix 2 (4.3)
NSCLC 2 (4.3)
Vulva 2 (4.3)
Ovarian 1 (2.2)
Previous therapy, n (%)
Surgery 31 (67.4)
Radiation 25 (54.3)
Chemotherapy 28 (60.9)
Hormonal 22 (47.8)
Other 10 (21.7)
Abbreviations: CRPC¼castration-resistant prostate cancer; ECOG¼Eastern
Cooperative Oncology Group; GOJ¼gastro-oesophageal junction; NSCLC¼non-
small cell lung cancer; PS¼performance status.
aIncludes two chondrosarcoma and
one peripheral nerve sheath tumour.
Table 2 Treatment summary
No. of cycles
Dose of figitumumab
Docetaxel Figitumumab
(mgkg
–1) n Median Range Median Range
0.1 3 6 3–8 10 3–13
0.4 3 6 5–8 10 5–10
0.8 3 4 3–13 10 4–14
1.5 3 3 2–12 3 2–17
33 6 2 – 1 0 8 2 – 1 2
6 3 7 2–8 7 2–8
10 9 4 2–10 4 2–10
20 19 4 1–10 4 1–21
Docetaxel was dosed at 75mgm
–2.
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sdrug, and included neutropaenia (n¼28), febrile neutropaenia
(n¼11), fatigue (n¼10), leukopaenia (n¼7), diarrhoea (n¼5),
lymphopaenia (n¼1), cellulitis (n¼1), deep-vein thrombosis
(n¼1), and pain (n¼1). There were no mitral valve changes
observed in serial echocardiograms as was the case in single-agent
figitumumab studies. No patients required therapy with GCSF or
GM-CSF. The MTD was not reached. Serum samples with
figitumumab concentrations below the LLOQ were screened for
ADA. Of the 60 ADA samples obtained from 17 patients, none was
positive for ADA (o3.32). The RP2D was the maximum feasible
dose of 20mgkg
–1of figitumumab in combination with 75mgm
–2
of docetaxel.
Pharmacokinetics
Plasma concentrations of figitumumab decreased in a multi-
exponential manner after an IV infusion (Figure 1A). The decline
in concentration was more rapid at the lower concentration range
than the higher concentration range. As shown in Table 4, the
plasma concentration at the end of infusion (C1h) and the AUC
within a cycle (AUC0–day22) increased with dose for cycles 1 and 4.
The increase in AUC0–day22 was approximately dose proportional.
After repeated administration, there was a moderate accumulation
in plasma exposure of figitumumab at dose levels of X3mgkg
–1,
with the mean accumulation ratio being approximately two-fold at
10 and 20mgkg
–1 (Table 4).
Evaluable docetaxel PK data acquired from the DDI expansion
cohort were available from 13 subjects in cycle 1 (without
figitumumab) and 5 subjects in cycle 4 (with figitumumab). The
dose-normalised docetaxel PK profiles seemed to be similar
between cycles 1 and 4. Figure 1B shows that in both cycles,
docetaxel concentration increased during the 1-h infusion and
decreased rapidly after the end of infusion. The dose-normalised
docetaxel PK profiles seemed to be similar between cycles 1 and 4.
The mean dose-normalised Cmax (Figure 1C) and AUClast
(Figure 1D) of docetaxel in both cycles were also comparable. Of
the five patients who had both cycles 1 and 4 docetaxel PK data,
there was no systematic pattern of change in dose-normalised Cmax
and AUClast between the two cycles. Overall, in the limited number
of patients evaluated, figitumumab did not seem to considerably
affect the PK of docetaxel.
Pharmacodynamics
All patients had detectable levels of sIGF-IR at study entry.
Treatment with figitumumab resulted in a dose-dependent
decrease in sIGF-IR, with higher doses translating to increasingly
longer periods of serum-marker downregulation. At 1.5 and
3mgkg
–1 of figitumumab, complete sIGF-IR downregulation was
achieved for the entire dosing period (Figure 2).
Circulating tumour cells X5 per 7.5ml of blood were
enumerated in 15 patients, including 10 with CRPC. Of these 10
patients with CRPC, 60% (6 of 10) showed a fall from X5 CTCs to
o5 CTCs, and 80% (8 of 10) showed a X30% fall in CTCs.
The maximal CTC fall for each of the 10 patients is shown in
Figure 3A. Of the remaining five patients, two had gastric
adenocarcinoma, two oesophageal adenocarcinoma, and one
ovarian cancer. There was a CTC fall from X5 per 7.5ml to o5
in one of the two patients with gastric cancers (results not shown);
the results of the patient with ovarian cancer were not evaluable.
The results of IGF-IR CTCs have been reported elsewhere (de Bono
et al, 2007).
Efficacy
A total of 39 patients (including 18 CRPC patients) were evaluable
for disease response. Four patients showed confirmed partial
responses (PR): three with CRPC and one with oesophageal cancer.
Figure 3B shows the response in pelvic nodal disease in a patient
with metastatic CRPC to the bones and nodes. A fifth patient with
CRPC showed an unconfirmed PR. All the radiologic responses
were observed at doses of figitumumab 43mgkg
–1. In all,
12 patients had a best response of stable disease (SD), including
eight with CRPC (SD range 6–16 months), one with chondro-
sarcoma (6 months), one with cervical cancer (7 months), one with
gastric cancer (6 months), and one with oesophageal cancer
(14 months). The remaining patients showed progressive disease.
Maximal prostate-specific antigen (PSA) declines of X30, X50,
and X90% were observed in 54% (12 of 22), 41% (9 of 22), and 5%
(1 of 22) of patients, respectively. The increases or declines in PSA
were confirmed with a second reading in a total of 17 patients and
these were the patients evaluable for a PSA outcome. The
percentage change in PSA from baseline to 12 weeks and maximal
PSA decline at any point are depicted for each patient as waterfall
plots in Figures 3C and D, respectively.
Of the six patients with CRPC whose CTCs fell from X5 per
7.5ml to o5 per 7.5ml, two showed a radiological PR alongside
X50 and X90% PSA decline, respectively. A third patient with
nonmeasurable disease showed a X50% PSA decline in the
presence of a CTC fall. In the remaining three patients, two showed
Table 3 Treatment-related adverse events
Toxicity Grade
No. of patients
(all cycles)
Figitumumab related
Elevated ALT 1/2 5
3/4 0
Elevated GGT 1/2 3
3/4 0
Fatigue 1/2 2
3/4 1
Hyperglycaemia 1/2 1
3/4 1
Muscle spasm 1/2 3
3/4 0
Nausea 1/2 3
3/4 0
Docetaxel related
Alopaecia 1/2 3
3/4 0
Anorexia 1/2 6
3/4 0
Cellulitis 1/2 0
3/4 1
Diarrhoea 1/2 8
3/4 5
Deep-vein thrombosis 1/2 1
3/4 1
Fatigue 1/2 16
3/4 9
Febrile neutropaenia
a 1/2 0
3/4 11
Leukopaenia 1/2 3
3/4 7
Lymphopaenia 1/2 2
3/4 1
Mucositis 1/2 4
3/4 0
Nausea 1/2 3
3/4 0
Neutropaenia 1/2 4
3/4 28
Pain 1/2 3
3/4 1
Abbreviations: ALT¼alanine aminotransferase; GGT¼g-glutamyl transferase.
aIncludes neutropenic sepsis.
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sstable radiological disease and PSAs and one showed radiological
and PSA PD. Of the four patients with adenocarcinomas of the
upper gastrointestinal tract, three (two oesophageal and one
gastric) showed a rise in CTCs from X5 per 7.5ml.
DISCUSSION
We have previously reported on the safety of single-agent
figitumumab, a potent fully human mAb against a key factor in
the IGF-1 system, IGF-IR (Haluska et al, 2007; Lacy et al, 2008). We
now present our findings from a phase Ib study of patients with
solid tumours using this mAb combined with the cytotoxic agent,
docetaxel. The combination therapy was well tolerated and the
previously reported figitumumab-related adverse events of hyper-
glycaemia and mild elevations in the liver transaminase enzymes
were manageable (Haluska et al, 2007; Lacy et al, 2008). One
patient with a past history of diabetes mellitus developed grade 4
hyperglycaemia. Steroid premedication and poor diabetic
control were implicated as primary causes of this hyperglycaemic
episode.
There was no apparent effect of figitumumab on the frequency
or severity of observed neutropaenia. Although haematologic
toxicity has been reported with other single-agent IGF-IR
monoclonal antibodies such as MK-0646 and AMG-479 (Hidalgo
et al, 2008; Tolcher et al, 2009), this toxicity does not seem to be
significantly worsened when combined with chemotherapy, as
found in our study and those of Sarantopoulos et al (2008) and
Tolcher et al (2008). A preliminary report from a study by Tolcher
et al (2008), in which AVE1642 (another mAb to IGF-IR) was
combined with docetaxel in 14 patients, also reported no apparent
exacerbation of docetaxel toxicity.
Increasing doses of figitumumab resulted in increased plasma
concentrations of this antibody. The approximately two-fold
accumulation in figitumumab plasma levels after dosing at
X10mgkg
–1 every 21 days confirmed previous findings that the
dosing frequency of every 3 weeks is appropriate at these dose
levels (Haluska et al, 2007). The PK exposure parameters (C1hand
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Figure 1 Pharmacokinetics of figitumumab and docetaxel. (A) Mean (±s.d.) plasma concentration–time profiles of figitumumab in cycles 1 and 4 when
given in combination with docetaxel. (B) Dose-normalised docetaxel concentration–time profile in cycles 1 and 4. (C) Dose-normalised Cmax in the
absence and presence of figitumumab. (D) Dose-normalised AUClast in the absence and presence of figitumumab (open circles indicate individual
observations; short line indicates mean values; and dashed line joins observations in cycles 1 and 4 from the same patients). Abbreviations:  figitumumab,
without figitumumab; þfigitumumab, with figitumumab.
Table 4 Pharmacokinetic parameters (mean±s.d.) of figitumumab given in combination with docetaxel
Cycle 1 Cycle 4
Dose (mgkg
–1) nC 1h (mgl
–1)
AUC0–day22
(mghl
–1) n
C1h
(mgl
–1)
Cday22
(mgl
–1)
AUC0–day22
(mghl
–1)
Accumulation
ratio
0.1 3 1.34±0.36 — 2 1.04, 1.54 — — —
0.4 3 7.42±0.82 1010±164 3 6.9±1.75 — 774±40 0.78±0.16
0.8 3 17.9±6.8 2050±649 3 17.8±2.1 0.288
a 2290±82 1.1±0.3
1.5 3 32.3±4.2 5110±2640 1 54.6 12.4 1260 1.5
3 3 57.7±23.7 10500±3750 2 75.5, 126 31.4, 33.1 25500, 24600 2.2, 1.8
6 3 129±24 26700±2770 2 203, 172 57.1, 37.2 46400, 40900 1.7, 1.4
10 9 211±33
b 38200±8000 7 324±48
c 57.6, 101
d 72400±18900 1.8±0.4
20 6 407±160
e 82100±23500 5 658±185 199±73
f 158000±64300 2.0±0.7
Abbreviations: AUC0–day22¼area under the plasma concentration–time curve from time 0 to day 22; C1h¼plasma concentration at 1h after the end of infusion;
Cday22¼plasma concentration at day 22 of the cycle. n indicates the number of patients included in the analysis.
an¼1.
bn¼8.
cn¼6.
dn¼2.
en¼5.
fn¼4.
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sAUC0–day22) of figitumumab when combined with docetaxel were
similar to those of single-agent figitumumab (Haluska et al, 2007),
indicating that this combination does not considerably alter
figitumumab PK parameters. Furthermore, in a limited number of
patients, figitumumab did not seem to substantially affect the PKs
of docetaxel. These results suggest that figitumumab at dose levels
up to 20mgkg
–1 can be safely administered with docetaxel, with
minimal docetaxel dose modification.
Administration of docetaxel and figitumumab in combination
resulted in decreased sIGF-IR levels. At doses X3mgkg
–1, there
was a complete downregulation of sIGF-IR levels for the entire
dosing cycle (Figure 2). This finding is consistent with the
extended PK and PD properties of figitumumab previously
reported (Haluska et al, 2007; Lacy et al, 2008).
It is interesting that sIGF-IR levels in patients receiving
figitumumab at doses of 0.1–0.8mgkg
–1 resulted in levels higher
than those observed at baseline, suggesting an intracellular
feedback mechanism that can overcome the temporal lack of
IGF-IR signalling. These preliminary data and those already
published on the potential application of CTCs expressing
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Figure 2 Mean concentration–time profiles of soluble IGF-IR after intravenous administration of figitumumab and docetaxel every 3 weeks.
Concentrations of soluble IGF-IR were expressed as a percentage of individual pre-treatment baseline concentrations. Here, N indicates the number of
patients with at least one measurement after the start of cycle 1 dosing.
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Figure 3 Efficacy of figitumumab and docetaxel in patients with CRPC. (A) Waterfall plot of maximal CTC declines in individual patients with baseline
CTC count of X5 per 7.5ml, treated with figitumumab and docetaxel. Dotted lines indicate CTC declines of 30, 50, and 90%, respectively. (B) Radiologic
response in a patient with metastatic disease to bilateral pelvic nodes. This patient also had extensive retroperitoneal (not shown) and bony metastases with
a baseline PSA of 11291mgl
–1. Bilateral pelvic nodal metastatic deposits are indicated by circles at baseline (pre-treatment image). After four cycles of
therapy, nodal disease showed a significant reduction in size (post-treatment image); PSA fell to a nadir of 1578mgl
–1. The patient completed eight cycles of
treatment with a maintained radiologic response, but with PSA progression and docetaxel-related fatigue. (C) Waterfall plot of PSA change from baseline to
12 weeks. (D) Waterfall plot of maximal PSA change for individual patients. Dotted lines indicate PSA declines of 30, 50, and 90%. Some patients had a PSA
decline on study but this was short lived and PSA then rose again, explaining why the week 12 and maximal PSA declines are different. Abbreviations: CRPC,
castration-resistant prostate cancer; CTC, circulating tumour cells; PSA, prostatic-specific antigen.
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sIGF-IR (de Bono et al, 2007) support the ongoing analysis of PD
end points, with a view to identifying predictive biomarkers of
response to this and other agents in this class of drugs (Carden
et al, 2009). In this study, IGF-IRþ CTCs were detected in all
patients with X5 CTCs per 7.5ml at enrolment (de Bono et al,
2007). These patients had higher PSA levels than those patients
who were IGF-IR CTC negative and were also more likely to show
PSA declines of 450%. From this we suggested a potential for the
use of IGF-IR positivity on CTCs as a molecular marker for
identifying patients with CRPC who may benefit from anti-IGF-IR
therapies (de Bono et al, 2007).
Although the demonstration of objective responses is not
a key end point in phase I studies, clinical assessment of response
to therapy in this study was of interest. Out of 22 patients with
CRPC, 4 showed a confirmed PR, and 54, 41, and 5% of patients
showed X30, X50, and X90% falls in PSA, respectively, on
therapy. In addition, a X30% fall in CTC counts was observed in
80% of patients who had X5 CTCs at baseline. Previous studies
have shown that patients who convert from a CTC count X5a t
baseline to o5 after therapy had significantly better overall
survival than those who did not (de Bono et al, 2008; Olmos et al,
2009). In addition, CTC counts were found to be an independent
predictor of time to disease progression as well as survival.
Half of the patients whose CTCs fell from X5t op5 cells per
7.5ml showed a radiological and/or PSA response; the numbers are
small but this supports the use of CTCs as a biomarker of
response. As a result of the activity observed in patients with
CRPC, a randomised phase II study of figitumumab in combina-
tion with docetaxel and prednisone vs docetaxel and prednisone
alone in patients with CRPC was initiated and is now close to
completion.
A patient with oesophageal cancer completed a total of 18
courses of figitumumab (including an initial 10 courses of the
treatment combination), achieving a PR after 4 cycles of the
combination that was maintained until disease progression after 18
cycles. A second patient with oesophageal cancer completed 21
cycles of the antibody (including 10 with the combination) with a
best response of SD, and complete resolution of tumour-associated
dysphagia. This suggests that potentiation of the therapeutic
effects of cytotoxic agents through a reversal of chemoresistance
can lead to meaningful clinical outcomes. Phase II and III studies
are ongoing to confirm efficacy in a number of tumour types,
including non-small cell lung cancer (NSCLC), Ewing’s sarcoma,
gastrointestinal cancers, and breast cancer. Interestingly, although
no clinical benefit was observed in the two patients with NSCLC
in this study, significant clinical activity with the combination
of figitumumab with paclitaxel and carboplatin over paclitaxel
and carboplatin alone was observed in a randomised phase II
study of 156 patients with NSCLC (Karp et al, 2009). In this
trial, 54% of patients responded to the combination, compared
with 42% of patients on paclitaxel and carboplatin alone. How-
ever, a randomised phase III study of this treatment combination
was terminated in December 2009 as it was deemed unlikely
to meet the primary end point of improved overall survival
compared with chemotherapy alone. Further analysis of the data
collected from this phase III study will determine whether it is
possible to select patients who will likely benefit from this
combination.
In conclusion, the combination of figitumumab at a maximum
feasible dose of 20mgkg
–1and docetaxel at 75mgm
–2is safe and
well tolerated in patients with advanced cancer, with no substantial
alteration in the PKs of either agent. Randomised phase II and III
studies of this, and other figitumumab treatment combinations,
are ongoing in subjects with various solid tumours.
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